Diagnosis and Treatment of Bipolar Disorder
JAMA · 10.10.2023 · 330 (14) · 1370
DOI: 10.1001/jama.2023.18588 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 10.10.2023. Verfasst von Andrew A Nierenberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Bipolar Disorder, Psychotropic Drugs. Die Arbeit wurde bisher 420-mal zitiert (Crossref) und nennt 82 Literaturangaben.
Abstract (Originalsprache)
Importance Bipolar disorder affects approximately 8 million adults in the US and approximately 40 million individuals worldwide. Observations Bipolar disorder is characterized by recurrent episodes of depression and mania or hypomania. Bipolar depressive episodes are similar to major depressive episodes. Manic and hypomanic episodes are characterized by a distinct change in mood and behavior during discrete time periods. The age of onset is usually between 15 and 25 years, and depression is the most frequent initial presentation. Approximately 75% of symptomatic time consists of depressive episodes or symptoms. Early diagnosis and treatment are associated with a more favorable prognosis. Diagnosis and optimal treatment are often delayed by a mean of approximately 9 years following an initial depressive episode. Long-term treatment consists of mood stabilizers, such as lithium, valproate, and lamotrigine. Antipsychotic agents, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine, are recommended, but some are associated with weight gain. Antidepressants are not recommended as monotherapy. More than 50% of patients with bipolar disorder are not adherent to treatment. Life expectancy is reduced by approximately 12 to 14 years in people with bipolar disorder, with a 1.6-fold to 2-fold increase in cardiovascular mortality occurring a mean of 17 years earlier compared with the general population. Prevalence rates of metabolic syndrome (37%), obesity (21%), cigarette smoking (45%), and type 2 diabetes (14%) are higher among people with bipolar disorder, contributing to the risk of early mortality. The annual suicide rate is approximately 0.9% among individuals with bipolar disorder, compared with 0.014% in the general population. Approximately 15% to 20% of people with bipolar disorder die by suicide. Conclusions and Relevance Bipolar disorder affects approximately 8 million adults in the US. First-line therapy includes mood stabilizers, such as lithium, anticonvulsants, such as valproate and lamotrigine, and atypical antipsychotic drugs, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dauten Family Center for Bipolar Treatment Innovation, Massachusetts General Hospital, Boston.
- Harvard Medical School, Boston, Massachusetts.
- Deakin University, IMPACT - the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
- Department for Affective Disorder, Aarhus University Hospital, Aarhus, Denmark.
- Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Zitieren
APA
Nierenberg, A. A., Agustini, B., Köhler-Forsberg, O., Cusin, C., Katz, D., Sylvia, L. G., Peters, A., & Berk, M. (2023). Diagnosis and Treatment of Bipolar Disorder. JAMA, 330(14), 1370. https://doi.org/10.1001/jama.2023.18588
Vancouver
Nierenberg AA, Agustini B, Köhler-Forsberg O, Cusin C, Katz D, Sylvia LG, et al. Diagnosis and Treatment of Bipolar Disorder. JAMA. 2023;330(14):1370. doi:10.1001/jama.2023.18588
BibTeX
@article{Nierenberg2023,
author = {Nierenberg, Andrew A and Agustini, Bruno and Köhler-Forsberg, Ole and Cusin, Cristina and Katz, Douglas and Sylvia, Louisa G and Peters, Amy and Berk, Michael},
title = {Diagnosis and Treatment of Bipolar Disorder},
journal = {JAMA},
year = {2023},
volume = {330},
number = {14},
pages = {1370},
doi = {10.1001/jama.2023.18588}
}
EUVIMED